The OUtMATCH Study

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults

Our researchers are trying to determine if a study medication called omalizumab alone or combined with oral immunotherapy may help people with multiple food allergies. Participants must have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut.

Enrollment: This trial is active and currently enrolling.

How to Participate: For more information, call 214-456-1438 or email foodallergyresearch@childrens.com

Who Can Participate: Anyone between the ages of 1-55 years who has a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut or walnut.

Age Range: 1-55 years

Gender: Any

Estimated Time Commitment (# of visits, etc.): This is a multi-stage study, with an individual study participation of up to 4 years and 8 months, but not past December 2023.

Study Location: Children’s Medical Center, Dallas

Compensation: Provided

Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Site Principal Investigator:J. Andrew Bird, MD

Study Coordinator: Amy Arneson, RN

Study Primary Investigator: Robert Wood, MD

For more information, please contact: foodallergyresearch@childrens.com